BOSTON, March 27, 2025 /PRNewswire/ -- Temu has been included in USA TODAY's "America's Best Stores 2025" ranking. This list recognizes 500 companies—both brick-and-mortar and online—that offer exceptional shopping experiences in the United States. Temu is the youngest company in the "mass merchant and variety" category, joining established platforms such as Amazon and eBay.
The rankings, developed by USA Today in collaboration with research partner Plant-A Insights Group, were based on public data and a large-scale confidential online survey of U.S. customers. More than 65,000 customers contributed nearly half a million reviews, evaluating stores on several criteria:
To ensure reliability, respondents evaluated only stores they had personally used in the past three years. Companies with major data breaches, recalls, lawsuits, or ethical concerns were excluded.
Temu is popular for offering a wide selection of affordable, quality products, helping consumers stretch their budgets. American businesses have been joining Temu, attracted by opportunities to expand their reach and attract new customers. More than half of Temu's U.S. sales are now locally fulfilled, reflecting the company's efforts to offer more products by local businesses and shorten delivery times for consumers.
About Temu:
Temu is a global e-commerce company that connects consumers with millions of business partners, manufacturers, and brands with a mission to enable them to live a better life. Temu is committed to offering affordable products to enable consumers and business partners to realize their dreams in an inclusive environment. Temu began operations in the United States in September 2022 and is now available in more than 90 markets worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Temu Recognized in USA TODAY's 2025 Best Stores List
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research
FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative diseases.
Phosphorylated tau has emerged as a critical biomarker for early detection and monitoring of Alzheimer's disease and other tauopathies. The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between peripheral and central tau species. This allows for the simultaneous measurement of two suites of multiple pTaus and tTau species, one specific for brain-derived and one combining brain- and peripheral tissue-derived Tau species.
"Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq CNS Disease 120 Panel, we are enabling scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This advancement is poised to accelerate biomarker-driven research and drug development in Alzheimer's Disease and related neurodegenerative disorders."
"The ability to detect brain-derived pTau species directly from blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease (AD) and related disorders," said Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health. "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. Recent evidence has underlined the importance of being able to detect brain-derived pTau for greater specificity for AD. Alamar's new CNS panel offers an unprecedented opportunity to further improve the diagnostic accuracy and clinical utilities of these biomarkers, which will dramatically impact patient care and clinical research."
Alamar Biosciences remains committed to partnering with the neuroscience community to unlock biomarker insights that drive earlier diagnosis, patient stratification, and therapeutic monitoring.
For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomic solutions, visit www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGOâ„¢ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
